InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
0
T+90 hit rate
33%
T+90 mean return
-3.3%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Kenny John P., Chairman & CEO. Officer active across 4 companies, notably Meridian Bioscience INC. In total, 15 reports have been published. Breakdown: 1 buy · 0 sell. Total volume traded: €144k. History available since 4 November 2021. The latest transaction was disclosed on 17 December 2025 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations15 total
10,286 shares@ US$2.4638.6% of flowCommon StockSEC:0001470831-25-000448:0
6,118 shares@ US$3.26949.7% of flowCommon StockSEC:0001470831-25-000232:0
6,657 shares@ US$3.0082100.0% of flowCommon StockSEC:0001062993-25-012140:0
71,017 shares0Common StockSEC:0001062993-25-009567:0
1,385 shares@ US$3.55251.9% of flowCommon StockSEC:0001062993-25-006390:0
47,659 shares@ US$3.172960.4% of flowCommon StockSEC:0001062993-25-003842:0
Ideal exit: 24 Nov 2025 (T+270)
23,256 shares@ US$4.3037.7% of flowCommon StockSEC:0001062993-24-016411:0
114,285 shares0Class A Common StockSEC:0001140361-23-026411:0
47,060 sharesCommon StockSEC:0001567619-23-001530:0
4,271 shares@ US$32.016.4% of flowCommon StockSEC:0001127602-22-025087:0
40,269 shares@ US$31.5359.4% of flowCommon StockSEC:0001127602-22-023690:0
13,559 shares@ US$10.100.17% mcap17.5% of flowCommon StockSEC:0001127602-22-018184:0
44,651 shares@ US$14.500.80% mcap82.5% of flowCommon StockSEC:0001127602-22-018097:0
155,511 sharesCommon StockSEC:0001127602-21-029297:0
56,472 shares0Common StockSEC:0001127602-21-028572:0
15 of 15 declarations
About Kenny John P.
John P. Kenny is the Chief Executive Officer of Meridian Bioscience Inc. He leads the company by defining growth strategies and overseeing operations. With a strong background in the industry, he is responsible for innovation and profitability, thereby contributing to Meridian Bioscience's leadership position in the market.
